Medtronic PLC said Monday that it agreed to acquire HeartWare International Inc. for $1.1 billion, adding more heart-treatment products to the medical-device maker.
Medtronic will pay $58 a share in cash for HeartWare, a 93% premium over HeartWare’s Friday closing price of $29.98. Before Monday, HeartWare’s stock had fallen 60% over the past year amid declining sales, problems with product studies and an acquisition—later terminated—that was seen as dilutive to Heartware.
The companies said Monday that the acquisition gives Medtronic more diagnostic tools and treatments for heart failure, a condition where the heart isn’t pumping enough blood to meet the body’s needs.
HeartWare makes surgical implants that mimic the heart’s blood-pumping function, known as ventricular assist devices. Medtronic estimated Monday that the global VAD market is about $800 million now and is expected to grow by a percentage in the mid-to-high single digits in the current year and accelerate to a percentage in the high-single, low-double digits in future years.
The companies said they expect the deal to close during Medtronic’s second fiscal quarter, ending in late October.
Medtronic said it didn’t expect to adjust its fiscal 2017 revenue outlook or earnings because of the acquisition, and that it expected the deal to add to earnings in its third year.
In January 2015, Medtronic closed a $50 billion acquisition of Dublin-based Covidien that combined two of the world’s largest medical-supply companies. That deal allowed Medtronic to move its corporate headquarters from Minneapolis to Dublin in a so-called inversion deal that reduced the company’s tax burden.
Medtronic, for its fiscal year ended April 29, reported earnings of $3.54 billion on revenue of $28.83 billion. Heartware, in its most recent fiscal year ended Dec. 31, had a loss of $72.8 million on revenue of $276.8 million.
Last year, Medtronic rival St. Jude Medical Inc. agreed to pay $3.4 billion to acquire Thoratec Corp., another maker of VADs.
By Brittney Laryea
Source: Wall Street Journal
Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.
Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.
US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.
